RxDoctor Payments Data

Bethany Deaton, PA

Physician Assistant · Waco, TXNPI 1285215673

Payments from drug & device makers

$2,170in general payments, 2019–2025

Across 88 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$537
  • Afaxys, Inc.$175
  • Johnson & Johnson$139
  • Merck$122
  • Janssen Products, LP$80
  • plus $74 from 3 others

What the payments were for

  • Speaking & faculty fees$1758%
  • Food & beverage$1,91588%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company49$1,042
Gilead16$537
Afaxys, Inc.1$175
Johnson & Johnson9$139
Merck7$122
Janssen Products, LP1$80
Organon3$43
Abbott1$26
Mayne Pharma Commercial LLC1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$19,298
Medicare patients
111
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine39$120,371
BiktarvyBictegrav/Emtricit/Tenofov Ala29$118,158
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$53,776
JulucaDolutegravir/Rilpivirine12$42,367
VraylarCariprazine Hcl22$30,123
Estradiol68$3,584
SymbicortBudesonide/Formoterol Fumarate11$2,488
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,636
Albuterol Sulfate HfaAlbuterol Sulfate40$1,322
Fluconazole16$1,230
Clonidine12$1,166
ValacyclovirValacyclovir Hcl18$725
Atorvastatin Calcium54$518
Carvedilol11$307
Potassium Chloride24$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca$1,042$162,73751 claims
GileadBiktarvy$537$118,15829 claims
Janssen Products, LPSymtuza$80$53,77612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →